ProPhase Labs Inc  

(Public, NASDAQ:PRPH)   Watch this stock  
Find more results for PRPH
-0.04 (-2.42%)
Real-time:   10:22AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.61 - 1.61
52 week 1.47 - 2.98
Open 1.61
Vol / Avg. 3,660.00/201,828.00
Mkt cap 26.82M
P/E     -
Div/yield     -
EPS -0.05
Shares 16.66M
Beta 0.91
Inst. own 13%

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -13.03% 1.62%
Operating margin -13.00% 1.66%
EBITD margin - 2.63%
Return on average assets -18.59% 2.38%
Return on average equity -25.39% 3.37%
Employees 50 -
CDP Score - -


United States - Map
+1-215-3450919 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


ProPhase Labs, Inc. is a manufacturer, marketer and distributor of a ranges of homeopathic and health products that are offered to the general public. The Company is also engaged in the research and development of potential over-the-counter (OTC) drugs, natural base health products along with supplements, personal care and cosmeceutical products. The Company's primary business is manufacturing, distribution, marketing and selling of OTC cold remedy products to consumers through food, multi-outlet pharmacy and chain drug stores, wholesalers and mass merchandisers. The Company's brand is Cold-EEZEO Cold Remedy and the Company's principal product is Cold-EEZEO zinc gluconate lozenges, used to reduce the duration and severity of symptoms of the common cold. In August 2011, the Company launched Cold-EEZE Oral Spray.

Officers and directors

Ted William Karkus Chairman of the Board, Chief Executive Officer
Age: 53
Bio & Compensation  - Reuters
Robert V. Cuddihy Jr. Chief Financial Officer, Chief Operating Officer, Executive Vice President
Age: 53
Bio & Compensation  - Reuters
Mark A. Burnett Independent Director
Age: 53
Bio & Compensation  - Reuters
Mark Frank Independent Director
Age: 51
Bio & Compensation  - Reuters
Louis Gleckel M.D. Independent Director
Age: 57
Bio & Compensation  - Reuters
Mark Leventhal Independent Director
Age: 64
Bio & Compensation  - Reuters
James T. McCubbin Independent Director
Age: 49
Bio & Compensation  - Reuters